101 Lindenwood Drive
About Velicept TherapeuticsVelicept Therapeutics is a privately held, clinical development company focused on advancing best-in-class compounds with the potential to fill unmet medical needs. Its lead program, solabegron, is a highly differentiated novel compound being investigated for overactive bladder (OAB) and irritable bowel syndrome (IBS). Velicept is a portfolio company of NeXeption.
CEO: Dr. James C. Walker
CFO: Doug Gessl
CSO: Dr. Eliot Ohlstein
Head of Project Management: Dr. Jeffrey S. Shaver
Head of Operations: Ray Stevens
Head of Commercial Strategy: Kelly A. Copeland
Head of CMC and QA: Dale Bennyhoff
Please click here for Velicept's pipeline.
5 articles with Velicept Therapeutics
Velicept Therapeutics Announces Positive Top-Line Phase 2b Results for Solabegron in the Treatment of Overactive Bladder (OAB)
Velicept Therapeutics, a privately-held specialty pharmaceutical company dedicated to the development of best-in-class compounds for the treatment of urological and gastrointestinal disorders, announced that its next generation beta-3 adrenoceptor agonist solabegron met the primary endpoint in VEL-2002, a Phase 2b study in patients with overactive bladder (OAB).
Velicept Therapeutics Raises an Additional $15 Million in Series B Round, Initiates Phase 2b Study Evaluating Once Daily Dosing of Solabegron in Patients with Overactive Bladder (OAB) and Receives Issuance of Additional U.S. Patent
Additional Funding to Advance Phase 2b Development Program in OAB
Velicept Therapeutics Initiates First of Two Phase 2b Dose-Ranging Studies of Solabegron in Patients with Overactive Bladder (OAB); Finalizes Novel, Once Daily Formulation; and Receives U.S. Patent Covering OAB
Issuance of U.S. Patent No. 9,907,767 further expands Velicept’s patent portfolio covering Solabegron.
Velicept Therapeutics Announces FDA Acceptance Of IND Application Of Novel, Once-Daily Formulation Of Solabegron For The Treatment Of Overactive Bladder